Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD Medications
Sima A, Saberzadeh-Ardestani B, Vahedi H, Fakheri H, Mansour-Ghanaei F, Maleki I, Nasseri-Moghaddam S, Vosoghinia H, Ghadir M, Hormati A, Kasaeian A, Radmard A, Khosravi B, Malekzadeh M, Alatab S, Sadeghi A, Aminisani N, Poustchi H, Gonoudi E, Anushiravani A, Rayatpisheh M, Colombel J, Ungaro R, Malekzadeh R. Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD Medications. Archives Of Iranian Medicine 2022, 25: 17-25. PMID: 35128908, DOI: 10.34172/aim.2022.04.Peer-Reviewed Original ResearchConceptsInflammatory bowel disease patientsInflammatory bowel diseaseGastrointestinal symptomsAnti-tumor necrosis factorAssociated with increased hospitalization ratesBowel diseasePresence of inflammatory bowel diseaseAssociated with higher hospitalization ratesCOVID-19 outcomesAssociated with more severe outcomesAnti-TNF therapyInflammatory bowel disease medicationsHospitalization ratesNon-IBD patientsOutcomes of COVID-19Prospective cohort studyMultivariate logistic regressionEffect of inflammatory bowel diseaseCOVID-19 patientsAssociated with hospitalizationNo significant differenceHigher hospitalization ratesClinical characteristicsCohort studyNecrosis factor
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply